Literature DB >> 19680143

Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.

Shinji Higashi1, Darren J Moore, Ryoko Yamamoto, Michiko Minegishi, Kiyoshi Sato, Takashi Togo, Omi Katsuse, Hirotake Uchikado, Yoshiko Furukawa, Hiroaki Hino, Kenji Kosaka, Piers C Emson, Keiji Wada, Valina L Dawson, Ted M Dawson, Heii Arai, Eizo Iseki.   

Abstract

Missense mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common causes of both familial and sporadic forms of Parkinson disease and are also associated with diverse pathological alterations. The mechanisms whereby LRRK2 mutations cause these pathological phenotypes are unknown. We used immunohistochemistry with 3 distinct anti-LRRK2 antibodies to characterize the expression of LRRK2 in the brains of 21 subjects with various neurodegenerative disorders and 7 controls. The immunoreactivity of LRRK2 was localized in a subset of brainstem-type Lewy bodies (LBs) but not in cortical-type LBs, tau-positive inclusions, or TAR-DNA-binding protein-43-positive inclusions. The immunoreactivity of LRRK2 frequently appeared as enlarged granules or vacuoles within neurons of affected brain regions, including the substantia nigra, amygdala, and entorhinal cortex in patients with Parkinson disease or dementia with LBs. The volumes of LRRK2-positive granular structures in neurons of the entorhinal cortex were significantly increased in dementia with LBs brains compared with age-matched control brains (p < 0.05). Double immunolabeling demonstrated that these LRRK2-positive granular structures frequently colocalized with the late-endosomal marker Rab7B and occasionally with the lysosomal marker, the lysosomal-associated membrane protein 2. These results suggest that LRRK2 normally localizes to the endosomal-lysosomal compartment within morphologically altered neurons in neurodegenerative diseases, particularly in the brains of patients with LB diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19680143      PMCID: PMC2768772          DOI: 10.1097/NEN.0b013e3181b44ed8

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  59 in total

1.  Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy.

Authors:  K Hasegawa; H Kowa
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

2.  LRRK2 protein is a component of Lewy bodies.

Authors:  Xiongwei Zhu; Sandra L Siedlak; Mark A Smith; George Perry; Shu G Chen
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

3.  Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

Authors:  Shinji Higashi; Eizo Iseki; Ryoko Yamamoto; Michiko Minegishi; Hiroaki Hino; Koshiro Fujisawa; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Kenji Kosaka; Heii Arai
Journal:  Brain Res       Date:  2007-10-25       Impact factor: 3.252

4.  Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

Authors:  A M Cataldo; J L Barnett; C Pieroni; R A Nixon
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

5.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.

Authors:  Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch
Journal:  Nat Genet       Date:  2006-09-10       Impact factor: 38.330

6.  Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.

Authors:  Justus C Dächsel; Owen A Ross; Ignacio F Mata; Jennifer Kachergus; Mathias Toft; Ashley Cannon; Matt Baker; Jennifer Adamson; Mike Hutton; Dennis W Dickson; Matthew J Farrer
Journal:  Acta Neuropathol       Date:  2006-12-07       Impact factor: 17.088

Review 7.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

8.  Synphilin-1 is present in Lewy bodies in Parkinson's disease.

Authors:  K Wakabayashi; S Engelender; M Yoshimoto; S Tsuji; C A Ross; H Takahashi
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

9.  Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Authors:  Edward D Plowey; Salvatore J Cherra; Yong-Jian Liu; Charleen T Chu
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  39 in total

Review 1.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

Review 2.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

3.  Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.

Authors:  Jason Schapansky; Jonathan D Nardozzi; Fredrik Felizia; Matthew J LaVoie
Journal:  Hum Mol Genet       Date:  2014-03-27       Impact factor: 6.150

4.  LRRK2 secretion in exosomes is regulated by 14-3-3.

Authors:  Kyle B Fraser; Mark S Moehle; João P L Daher; Philip J Webber; Jeri Y Williams; Carrie A Stewart; Talene A Yacoubian; Rita M Cowell; Terje Dokland; Tong Ye; Dongquan Chen; Gene P Siegal; Robert A Galemmo; Elpida Tsika; Darren J Moore; David G Standaert; Kyoko Kojima; James A Mobley; Andrew B West
Journal:  Hum Mol Genet       Date:  2013-07-25       Impact factor: 6.150

Review 5.  Deregulation of autophagy and vesicle trafficking in Parkinson's disease.

Authors:  Patricia Sheehan; Zhenyu Yue
Journal:  Neurosci Lett       Date:  2018-04-05       Impact factor: 3.046

Review 6.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

Review 7.  Mechanisms of LRRK2-mediated neurodegeneration.

Authors:  Elpida Tsika; Darren J Moore
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

8.  Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.

Authors:  H Lee; H L Melrose; M Yue; Jean-Francois Pare; M J Farrer; Y Smith
Journal:  Exp Neurol       Date:  2010-05-17       Impact factor: 5.330

Review 9.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

Review 10.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.